ELC Group appoints former TOPRA president

Dr Paolo Biffignandi joins ELC Group’s Advisory Board

Dr Paolo Biffignandi, former president of The Organisation for Professionals in Regulatory Affairs (TOPRA), has joined the ELC Group’s Advisory Board. ELC is a pan-European pharmaceutical regulatory affairs organisation.

Dr Biffignandi, a renowned physician, with PhDs in endocrinology and pharmacology, is a Fellow of TOPRA, as well as an Overseas Fellow of the Royal Society of Medicine (UK). He brings more than 30 years' experience in Regulatory Affairs and pharmacovigilance to ELC Group’s Advisory Board.

Commenting on his appointment, Dr Biffignandi said: 'ELC Group is the industry expert, and I'm pleased to accept this opportunity to join its Advisory Board and to contribute to its continued strategic success.'

You may also like

Regulatory

ELC Group signs €1.5m regulatory affairs contract with Chinese pharma company

Endorses its Concept to Commercialisation approach to regulatory affairs consultancy services
Regulatory

ELC Group expands corporate presence in Czech Republic

Major contract wins in China and US fuel latest move into larger premises in Prague
Regulatory

ELC Group expands its offices in Ahmedabad, India

Regulatory affairs specialist continues its growth in the country
Regulatory

ELC Group opens new office in Mumbai, India

To be headed by Pooja Raj, general manager, regulatory affairs
Regulatory

ELC Group establishes global hq in Cambridge, UK

Follows year of exceptional revenue growth for regulatory affairs organisation
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Subscribe now